2017
DOI: 10.1183/16000617.0027-2016
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair qu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
46
0
3

Year Published

2017
2017
2023
2023

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 65 publications
(50 citation statements)
references
References 158 publications
(153 reference statements)
1
46
0
3
Order By: Relevance
“…10 The prevalence of chronic obstructive pulmonary disease (COPD) was found to be 23.1% in a large cohort of patients with ILDs, 11 and in another large cohort COPD was one of the most prevalent comorbidities in patients with ILD. 12,13 It is also interesting that the prevalence of CPFE among asymptomatic smokers is 3.1%. 14…”
Section: Definition and Epidemiologymentioning
confidence: 99%
“…10 The prevalence of chronic obstructive pulmonary disease (COPD) was found to be 23.1% in a large cohort of patients with ILDs, 11 and in another large cohort COPD was one of the most prevalent comorbidities in patients with ILD. 12,13 It is also interesting that the prevalence of CPFE among asymptomatic smokers is 3.1%. 14…”
Section: Definition and Epidemiologymentioning
confidence: 99%
“…The likely elevation of healthcare utilisation in patients with ILD arises in part from comorbidities in patients with ILD that include cardiovascular disease, malignancy, sleep apnoea and pulmonary hypertension (PH), and contribute to hospitalisations, physician visits and medication use [6,49,50]. Again, using the example of IPF, in a recent analysis of healthcare costs and utilisation in patients covered by Medicare in the USA, it was estimated that the total annual medical costs in 2000-2011 were up to USD 3 billion, of which USD 1.8 billion was attributable to IPF and associated comorbidities [13].…”
Section: Comorbiditiesmentioning
confidence: 99%
“…For example, World Health Organization group 3 PH is associated with substantially higher healthcare resource use than in control disease-matched patients, particularly in the number of prescription claims, outpatient visits and physician office visits [49]. Prevalence rates of comorbidities in IPF have been published with wide ranges, for example: PH 8-84%; cardiac disease 60%; lung cancer 4.4-10%; and sleep apnoea, 60-90% [49,50]. Based on a small number of results, rates of comorbidities in patients with other progressive-fibrosing ILDs may be similar to those in IPF.…”
Section: Comorbiditiesmentioning
confidence: 99%
“…Another unanticipated nding was comorbidity burden was not a predictor of HRQL decline. Comorbidities may impact treatment decisions and thus impair HRQL [37,38]. The association between a higher number of comorbidities and HRQL decline was shown in IPF cohorts [12].…”
Section: Discussionmentioning
confidence: 98%